BIOGEN INC. is 1.5x more valuable than Moderna, Inc. by market capitalization ($28.73 B vs $18.86 B). Every figure below comes from audited SEC filings and refreshed market data.
| Metric | BIIB | MRNA |
|---|---|---|
| Market cap | $28.73 B | $18.86 B |
| US-listed rank | #480 | #643 |
| Revenue (latest FY) | $9.89B | $1.94B |
| Net income (latest FY) | $1.29B | -$2.82B |
| Net margin | 13.1% | -145.2% |
| P/E (trailing FY) | 22.2 | - |
| SEC filings | 2,690 | 1,447 |
BIOGEN INC. is 1.5x more valuable than Moderna, Inc. by market capitalization ($28.73 B vs $18.86 B).
In their latest fiscal years, BIOGEN INC. reported $9.89B in revenue while Moderna, Inc. reported $1.94B.
Full pages: BIOGEN INC. and Moderna, Inc., or browse the full rankings.